

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 13, 2025

Brilliant Violet 421(TM) anti-mouse CD8a

RRID:AB_11204079

Type: Antibody

Proper Citation

(BioLegend Cat# 100738, RRID:AB_11204079)

Antibody Information

URL: http://antibodyregistry.org/AB_11204079

Proper Citation: (BioLegend Cat# 100738, RRID:AB_11204079)

Target Antigen: CD8alpha

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, IHC, SB

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD8a

Description: This monoclonal targets CD8alpha

Target Organism: mouse

Clone ID: Clone 53-6.7

Antibody ID: AB_11204079

Vendor: BioLegend

Catalog Number: 100738

Alternative Catalog Numbers: 100737, 100753

Record Creation Time: 20231110T055851+0000

Record Last Update: 20241115T112254+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD8a.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD8a.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ashayeripanah M, et al. (2024) Systemic inflammatory response syndrome triggered by blood-borne pathogens induces prolonged dendritic cell paralysis and immunosuppression. *Cell reports*, 43(2), 113754.

Park CS, et al. (2024) Fam49b dampens TCR signal strength to regulate survival of positively selected thymocytes and peripheral T cells. *eLife*, 13.

Ni S, et al. (2024) Identifying compound-protein interactions with knowledge graph embedding of perturbation transcriptomics. *Cell genomics*, 4(10), 100655.

Lin Y, et al. (2024) Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. *Med (New York, N.Y.)*, 100530.

Hulin-Curtis S, et al. (2024) A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. *Cell reports*, 43(6), 114259.

Yang Y, et al. (2024) Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. *Cell reports. Medicine*, 5(9), 101718.

Gräbnitz F, et al. (2023) Asymmetric cell division safeguards memory CD8 T cell development. *Cell reports*, 42(5), 112468.

McDonald B, et al. (2023) Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates. *Immunity*, 56(6), 1303.

Wu Z, et al. (2023) Pericyte stem cells induce Ly6G⁺ cell accumulation and immunotherapy resistance in pancreatic cancer. *EMBO reports*, 24(4), e56524.

Bayerl F, et al. (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. *Immunity*, 56(6), 1341.

Ma L, et al. (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. *Cell*, 186(15), 3148.

Okamoto M, et al. (2023) A genetic method specifically delineates Th1-type Treg cells and their roles in tumor immunity. *Cell reports*, 42(7), 112813.

Liang Z, et al. (2022) The proprotein convertase furin regulates the development of thymic epithelial cells to ensure central immune tolerance. *iScience*, 25(10), 105233.

Dähling S, et al. (2022) Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. *Immunity*, 55(4), 656.

Wang C, et al. (2021) Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. *Cell reports*, 37(8), 110021.

Sakamoto K, et al. (2021) Disruption of the endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate lymphoid cell-mediated hair follicle destruction. *Immunity*, 54(10), 2321.

Delacher M, et al. (2021) Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. *Immunity*, 54(4), 702.

Lutes LK, et al. (2021) T cell self-reactivity during thymic development dictates the timing of positive selection. *eLife*, 10.

Bambouskova M, et al. (2021) Itaconate confers tolerance to late NLRP3 inflammasome activation. *Cell reports*, 34(10), 108756.

Levine LS, et al. (2021) Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8⁺ T cells during the primary immune response. *Immunity*, 54(4), 829.